80 CHF CHF 80.00
AG-CR1-3582-M0055 mgCHF 80.00
AG-CR1-3582-M02525 mgCHF 320.00
|Synonyms||Resiquimod; S 28463; R848|
|Appearance||White to off-white powder.|
|Solubility||Soluble in DMSO, dichloromethane or methanol. Slightly soluble in acetonitrile or ethyl acetate.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
After reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Stable for at least 2 years after receipt when stored at -20°C.
Stock solutions are stable for at least 3 months when stored at -20°C.
|Product Specification Sheet|
- Immune response modifier. Potent antitumor and antiviral compound [1, 3, 10, 11, 13, -16].
- Stimulates antibody secretion and cytokine production .
- Used as adjuvant to increase the effectiveness of vaccines [2, 7, 9, 10].
- Potent and selective synthetic ligand for Toll-like receptor 7 (TLR7) in mouse and for TLR7 and TLR8 in human [4-6].
- Activates immune cells via the TLR7/TLR8 MyD88-dependent signaling pathway and leads to the induction of NF-κB .
- NLRP3/NALP3 inflammasome activator, independent of TLRs and RIG-I .
- Upregulator of the opioid growth factor receptor .
- Used in the treatment of skin lesions such as herpes simplex virus .
- Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod: T.L. Wagner, et al.; Cell Immunol. 191, 10 (1999)
- Adjuvant activities of immune response modifier R-848: comparison with CpG ODN: J.P. Vasilakos, et al.; Cell Immunol. 204, 64 (2000)
- The immune response modifier resiquimod mimics CD40-induced B cell activation: G.A. Bishop, et al.; Cell. Immunol. 208, 9 (2001)
- Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002)
- Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848: M. Jurk, et al.; Nat. Immunol. 3, 499 (2002)
- Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8: K.B. Gorden, et al.; J. Immunol. 174, 1259 (2005)
- TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848): R.D. Weeratna, et al.; Vaccine 23, 5263 (2005)
- Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3: T.D. Kanneganti, et al.; Nature 440, 233 (2006)
- Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination: R. Ma, et al.; BBRC 361, 537 (2007)
- Resiquimod and other immune response modifiers as vaccine adjuvants: M.A. Tomai, et al.; Expert Rev. Vaccines 6, 835 (2007) (Review)
- The antiviral activity of Toll-like receptor 7 and 7/8 agonists: R.L. Miller, et al.; Drug News Perspect. 21, 69 (2008) (Review)
- Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function: I.S. Zagon, et al.; Exp. Biol. Med. 233, 968 (2008)
- Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation: W. van den Ancker, et al.; Cancer Immunol. Immunother. 60, 37 (2011)
- Treatment with the TLR7 agonist R848 induces regulatory T-cell-mediated suppression of established asthma symptoms: L.P. Van, et al.; Eur. J. Immunol. 41, 1992 (2011)
- R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes: H. Nian, et al.; BMC Infect. Dis. 12, 5 (2012)
- Resiquimod|a topical drug for viral skin lesions and skin cancer: T. Meyer, et al.; Expert Opin. Investig. Drugs 22, 149 (2013)
- TLR7 agonists display potent antiviral effects against norovirus infection via innate stimulation: D.E. Tuipulotu, et al.; Antimicrob. Agents Chemother. 62, e02417 (2018)
- Systemic and intestinal porcine epidemic diarrhea virus-specific antibody response and distribution of antibody-secreting cells in experimentally infected conventional pigs: Vet. Res. 52, 2 (2021)